Disc Medicine, Inc. (IRON)
| Market Cap | 2.32B +22.8% |
| Revenue (ttm) | n/a |
| Net Income | -181.11M |
| EPS | -5.42 |
| Shares Out | 37.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 920,141 |
| Open | 62.80 |
| Previous Close | 63.35 |
| Day's Range | 60.46 - 63.07 |
| 52-Week Range | 30.82 - 99.50 |
| Beta | 2.58 |
| Analysts | Strong Buy |
| Price Target | 101.92 (+66.1%) |
| Earnings Date | Feb 27, 2026 |
About IRON
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the tre... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for IRON stock is "Strong Buy." The 12-month stock price target is $101.92, which is an increase of 66.10% from the latest price.
News
Disc Medicine, Inc. (IRON) Discusses FDA Complete Response Letter and Path Forward for Bitopertin Regulatory Approval Transcript
Disc Medicine, Inc. (IRON) Discusses FDA Complete Response Letter and Path Forward for Bitopertin Regulatory Approval Transcript
Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route
Disc Medicine said on Tuesday it will pursue a traditional U.S. approval pathway for its rare disease drug after the Food and Drug Administration declined to approve the treatment under a new fast-tra...
US FDA declines to approve Disc Medicine's rare disease drug
Disc Medicine said on Friday the U.S. Food and Drug Administration has declined to approve its drug to treat a rare genetic disorder, sending its shares down 31.6% to $48.90.
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
WATERTOWN, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for ...
Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action
The U.S. Food and Drug Administration (FDA) reviewers on Thursday postponed their decision on an experimental treatment from Disc Medicine Inc. (NASDAQ: IRON) by about two weeks to Feb.10.
Disc Medicine, Inc. (IRON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Disc Medicine, Inc. (IRON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine: RALLY-MF Data Validates Pipeline Optionality
Disc Medicine is well-capitalized, with over $800M in cash, ensuring operational runway through 2029 regardless of bitopertin's launch success. Bitopertin's NDA is submitted, aiming for accelerated FD...
Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript
Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
WATERTOWN, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine, Inc. (IRON) Presents at Jefferies London Healthcare Conference 2025 Transcript
Disc Medicine, Inc. ( IRON) Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM EST Company Participants John Quisel - CEO, President & Director Conference Call Participants Jiale S...
Disc Medicine, Inc. (IRON) Presents at Stifel 2025 Healthcare Conference Transcript
Disc Medicine, Inc. ( IRON) Stifel 2025 Healthcare Conference November 13, 2025 8:40 AM EST Company Participants Jonathan Yu - Chief Opearating Officer Conference Call Participants Stephen Willey - S...
Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...
Disc Medicine: NDA Submission And CNPV For Bitopertin Further Boost Shareholder Value
Disc Medicine receives a "Strong Buy" rating due to significant progress with bitopertin for EPP and XLP treatment. IRON submitted an NDA for bitopertin under Accelerated Approval, supported by positi...
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Disc Medicine, Inc. (IRON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Disc Medicine, Inc. (NASDAQ:IRON) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants John Quisel - CEO, President & Director Conference Call P...
Disc Medicine Appoints Nadim Ahmed to its Board of Directors
WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t...
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t...